Cannacord report-while we knew most of it, its nice to hear analysts become more confident and state the obvious 1 MNTA patent estate on characterization vs none for TEVA 2 NO HIT issues for generic
The continued weakness and churning of shares, and almost 5-6 million shorts is exasperating.